Ackermans & Van Haaren – link to home page Ackermans & Van Haaren – link to home page
Banner image

MRM Health

MRM Health

MRM Health, established in the Ghent biotech cluster, develops innovative human microbiome-based medicines.

Included in the AvH investment portfolio since 2020.

 

Visit website Back > Life sciences portfolio

16.92 %

Beneficial interest AvH

Press releases - Growth capital

View All
Growth Capital

Biotalys Achieves Critical Manufacturing Milestone for First Commercial Biofungicide EVOCA® NG

Read more
Growth Capital

Biotalys’ First Commercial Biofungicide EVOCA® NG Approved for Large-Scale Commercial Field Trials in the Netherlands

Read more

Related participations

Confo Therapeutics

Growth Capital

Confo Therapeutics

Confo's mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases, peripheral pain and obesity.

Read more
DISCO Pharmaceuticals

Growth Capital

DISCO Pharmaceuticals

DISCO Pharmaceuticals uses groundbreaking proteomics technology to map the cancer cell surfaceome. DISCO Pharmaceuticals has pioneered the initial surfaceome mapping for Small Cell Lung Cancer (SCLC) and Colorectal Cancer (CRC). The company is currently advancing multiple ADC candidates toward studies that will enable submission for Investigational New Drug (IND) status.

Read more
OncoDNA

Growth Capital

OncoDNA

OncoDNA supports cancer specialists by providing comprehensive characterization of a patient’s cancer.

Read more